Staff Profile

Hannah is a Royal Society University Research Fellow in Medicinal Chemistry at Newcastle University School of Natural and Environmental Sciences and the Newcastle University Centre for Cancer. Her research interests lie in beyond cysteine covalent drug discovery for the application to challenging, high value cancer targets.

Qualifications

MSc (Hons), MA, First Class, in Natural Sciences 2014 (Cambridge University)

PhD in Organic Chemistry 2018 (Cambridge University) with Prof. David Spring

Synthesis of partially saturated bicyclic heteroaromatics: sp³ enriched scaffolds for drug discovery

Previous Positions

January 2019 - July 2022: Post-doctoral researcher in the group of Prof. Mike Waring, CRUK Drug Discovery Unit, Newcastle University Centre for Cancer.

August 2022 – December 2025:  Senior Post-doctoral researcher in the group of Prof. Mike Waring, CRUK Drug Discovery Unit, Newcastle University Centre for Cancer.

Worked on the development of novel approaches to high value cancer targets with a focus on irreversible inhibition delivering potent covalent inhibitors across three projects. 

I teach first year undergraduate tutorials in Fundamentals of Organic Chemistry CHY1110.

• Articles

  • Morese PA, Ahmad A, Martin MP, Noble RA, Pintar S, Wang LZ, Xu S, Lister A, Ward RA, Bronowska A, Noble MEM, Stewart HL, Waring MJ. Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding. Communications Chemistry 2025, 8, 111.
  • Stewart HL, Bordoni C, Jennings CE, Al-Khawaldeh I, Martin MP, Noble RA, Phillips N, Pintar S, Prendergast L, Thomas HD, Wang L-Z, Watt JE, Wittner A, Bronowska AK, Cano C, Noble MEM, Wedge SR, Waring MJ. Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies. Journal of Medicinal Chemistry 2025.
  • Pirie R, Stanway-Gordon HA, Stewart HL, Wilson KL, Paton S, Tyerman J, Cole DJ, Fowler K, Waring MJ. An analysis of the physicochemical properties of oral drugs from 2000 to 2022. RSC Medicinal Chemistry 2024, 15(9), 3125-3132.
  • Morese PA, Anthony N, Bodnarchuk M, Jennings C, Martin MP, Noble RA, Phillips N, Thomas HD, Wang LZ, Lister A, Noble MEM, Ward RA, Wedge SR, Stewart HL, Waring MJ. Targeting cytotoxic agents through EGFR-mediated covalent binding and release. Journal of Medicinal Chemistry 2023, 66(17), 12324-12341.
  • Stewart HL, Bon M, Wills C, Martin MP, Wang L, Mackenzie ES, Wadell PG, Waring MJ. Conformational study into alkyl-aryl ureas to inform drug discovery . Bioorganic and Medicinal Chemistry 2023, 91, 117387.
  • Uguen M, Davison G, Sprenger LJ, Hunter JH, Martin MP, Turberville S, Watt JE, Golding BT, Noble MEM, Stewart HL, Waring MJ. Build–Couple–Transform: A paradigm for lead-like library synthesis with scaffold diversity. Journal of Medicinal Chemistry 2022, 65(16), 11322-11339.
  • Al-Khawaldeh I, Aldred GG, Alyassiri M, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Miller DC, Shrives HJ, de Souza JV, Stewart HL, Temple M, Totobenazara J, Tucker JA, Tudhope SJ, Wang LZ, Bronowska AK, Cano C, Endicott JA, Golding BT, Hardcastle IR, Hickson I, Wedge SR, Willmore E, Noble MEM, Waring MJ. An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK). Journal of Medicinal Chemistry 2021, 64(14), 10001-10018.